Form 8-K - Current report:
SEC Accession No. 0000950170-24-124542
Filing Date
2024-11-12
Accepted
2024-11-12 07:05:07
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apge-20241112.htm   iXBRL 8-K 41771
2 EX-99.1 apge-ex99_1.htm EX-99.1 157391
3 GRAPHIC img126220792_0.jpg GRAPHIC 39553
  Complete submission text file 0000950170-24-124542.txt   380126

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20241112.xsd EX-101.SCH 24879
15 EXTRACTED XBRL INSTANCE DOCUMENT apge-20241112_htm.xml XML 4724
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 241443210
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)